CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely ...

In data presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, the two-year study finds ...

Here’s what to know about the irreversible eye disease at the center of the new National Geographic documentary Blink.

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has announced positive results from its ongoing clinical trials for ...

Up to half of patients showed significant improvement in study results presented at the American Academy of Ophthalmology ...

Researchers have identified new drug targets for therapies that could benefit patients with different forms of retinitis ...

Retinitis pigmentosa is a leading cause of blindness in adults. This CEO leads a Dallas company aiming to develop the first ...

Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with ...

One form, retinitis pigmentosa, belongs to a group of eye conditions that affects around 1 in 4,000 people in the United States and 1 in 5,000 people worldwide. This form of retinitis is typically ...

An international team of researchers has identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases ...